Showing results 1 to 20 of 24
next >
| Preview | Issue Date | Title | Author(s) |
| 2011 | Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo | Zinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Findlay, D.; Zannettino, A.; Evdokiou, A. |
| 2009 | Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma | Labrinidis, A.; Diamond, P.; Martin, S.; Hay, S.; Liapis, V.; Zinonos, I.; Sims, N.; Atkins, G.; Vincent, C.; Ponomarev, V.; Findlay, D.; Zannettino, A.; Evdokiou, A. |
| 2009 | Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer | Zinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Zannettino, A.; Findlay, D.; Evdokiou, A. |
| 2002 | Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism | Findlay, D.; Raggatt, L.; Bouralexis, S.; Hay, S.; Atkins, G.; Evdokiou, A. |
| 2002 | Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to APO2L/TRIAL-induced apoptosis | Evdokiou, A.; Bouralexis, S.; Atkins, G.; Chai, F.; Hay, S.; Clayer, M.; Findlay, D. |
| 2001 | Chemotherapeutic drugs sensitise osteogenic sarcoma cells but not normal human bone cells to TRAIL-mediated apoptosis | Atkins, G.; Evdokiou, A.; Bouralexis, S.; Chai, F.; Hay, S.; Clayer, M.; Findlay, D. |
| 2008 | Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males | Findlay, D.; Chehade, M.; Tsangari, H.; Neale, S.; Hay, S.; Hopwood, B.; Pannach, S.; O'Loughlin, P.; Fazzalari, N. |
| 1999 | Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells | Gronthos, S.; Zannettino, A.; Graves, S.; Ohta, S.; Hay, S.; Simmons, P. |
| 2008 | Does Apo2LTRAIL play any physiologic role in osteoclastogenesis? | Labrinidis, A.; Liapis, V.; Thai, L.; Atkins, G.; Vincent, C.; Hay, S.; Sims, N.; Zannettino, A.; Findlay, D.; Evdokiou, A. |
| 2001 | Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL | Clayer, M.; Bouralexis, S.; Evdokiou, A.; Hay, S.; Atkins, G.; Findlay, D. |
| 2000 | Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells | Kitahama, S.; Gibson, M.; Hatzinikolas, G.; Hay, S.; Kuliwaba, J.; Evdokiou, A.; Atkins, G.; Findlay, D. |
| 2000 | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors | Atkins, G.; Haynes, D.; Graves, S.; Evdokiou, A.; Hay, S.; Bouralexis, S.; Findlay, D. |
| 2002 | Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis | Atkins, G.; Bouralexis, S.; Evdokiou, A.; Hay, S.; Labrinidis, A.; Zannettino, A.; Haynes, D.; Findlay, D. |
| 2004 | In vitro osteosarcoma biosensing using THz time domain spectroscopy | Ferguson, B.; Liu, H.; Hay, S.; Findlay, D.; Zhang, X.; Abbott, D.; Faraone, L.; Vardan, V.K.; Microelectronics, MEMS, and Nanotechnology 2003 (10 December 2003 : Perth, Australia) |
| 2003 | Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis | Evdokiou, A.; Labrinidis, A.; Bouralexis, S.; Hay, S.; Findlay, D. |
| 1997 | Integrin Expression and Function on Human Osteoblast-like Cells | Gronthos, S.; Stewart, K.; Graves, S.; Hay, S.; Simmons, P. |
| 2003 | Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy | Bouralexis, S.; Findlay, D.; Atkins, G.; Labrinidis, A.; Hay, S.; Evdokiou, A. |
| 1997 | Regulation of bone cells by particle-activated mononuclear phagocytes | Haynes, D.; Hay, S.; Rogers, S.; Ohta, S.; Howie, D.; Graves, S. |
| 2004 | Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin | Bouralexis, S.; Clayer, M.; Atkins, G.; Labrinidis, A.; Hay, S.; Graves, S.; Findlay, D.; Evdokiou, A. |
| 2005 | Synergistic induction of prostate cancer cell death by g-tocotrienol and lovastatin is mediated by direct geranylgeranyl pyrophosphate inhibition through a caspase-independent pathway | Odysseos, A.; Vraka, P.; Liapis, V.; Hay, S.; Evdokiou, A. |
